Dexamethasone Therapy in VLBW Infants at Risk of CLD

Not Recruiting

Trial ID: NCT00011362


Infants who are on breathing support are often treated with steroids (dexamethasone); however, the best timing of therapy is not known. This trial looked at the benefits and hazards of starting dexamethasone therapy at two weeks of age and four weeks of age in premature infants.

Official Title

Randomized Clinical Trial of Dexamethasone Therapy in Very-Low-Birth-Weight Infants at Risk for Chronic Lung Disease (CLD)

Stanford Investigator(s)


Inclusion criteria:

   - 501 to 1500 grams

   - 13 to 15 days old

   - Respiratory-index score of greater than or equal to 2.4 that had been increasing or
   minimally decreasing during the previous 48 hours or a score of greater than or equal
   to 4.0 even if there had been improvement during the preceding 48 hours

Exclusion criteria:

   - Received glucocorticoid treatment after birth

   - Had evidence or suspicious signs of sepsis as judged by the treating physician

   - Major congenital anomaly of the cardiovascular, pulmonary, or central nervous system


drug: Dexamethasone Early

drug: Dexamethasone Late

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305